Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
The post-marketing incidence of TRAEs with nivolumab in patients with MPM has been evaluated, and no new safety signals were identified compared to the phase II clinical trial in Japan.
Authors
- Nobukazu Fujimoto (ORCID: https://orcid.org/0000-0002-4516-0433)
- Chikara Honda (ORCID: https://orcid.org/0000-0003-1005-7505)
- Yuichiro Ohe (ORCID: https://orcid.org/0000-0002-6137-073X)
- Ayumi Akamatsu
- Miki Aoki
Institutions
- National Cancer Center (US)
- Ono Pharmaceutical (Japan) (JP)
- Okayama Rosai Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1093/jjco/hyae119
- Citations
- 1
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical